Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

USA - NASDAQ:SNGX - US8342236044 - Common Stock

1.38 USD
+0.1 (+7.81%)
Last: 10/3/2025, 8:04:27 PM
1.38 USD
0 (0%)
After Hours: 10/3/2025, 8:04:27 PM
Fundamental Rating

2

SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. The financial health of SNGX is average, but there are quite some concerns on its profitability. SNGX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNGX has reported negative net income.
In the past year SNGX has reported a negative cash flow from operations.
In the past 5 years SNGX always reported negative net income.
SNGX had a negative operating cash flow in each of the past 5 years.
SNGX Yearly Net Income VS EBIT VS OCF VS FCFSNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

SNGX has a worse Return On Assets (-184.80%) than 89.93% of its industry peers.
SNGX has a Return On Equity of -582.04%. This is in the lower half of the industry: SNGX underperforms 78.54% of its industry peers.
Industry RankSector Rank
ROA -184.8%
ROE -582.04%
ROIC N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNGX Yearly ROA, ROE, ROICSNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

SNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNGX Yearly Profit, Operating, Gross MarginsSNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNGX has been increased compared to 1 year ago.
Compared to 5 years ago, SNGX has more shares outstanding
Compared to 1 year ago, SNGX has an improved debt to assets ratio.
SNGX Yearly Shares OutstandingSNGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SNGX Yearly Total Debt VS Total AssetsSNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

SNGX has an Altman-Z score of -63.72. This is a bad value and indicates that SNGX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -63.72, SNGX is not doing good in the industry: 94.03% of the companies in the same industry are doing better.
There is no outstanding debt for SNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -63.72
ROIC/WACCN/A
WACC10.41%
SNGX Yearly LT Debt VS Equity VS FCFSNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

SNGX has a Current Ratio of 1.47. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
SNGX's Current ratio of 1.47 is on the low side compared to the rest of the industry. SNGX is outperformed by 80.78% of its industry peers.
A Quick Ratio of 1.47 indicates that SNGX should not have too much problems paying its short term obligations.
SNGX has a Quick ratio of 1.47. This is amonst the worse of the industry: SNGX underperforms 80.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
SNGX Yearly Current Assets VS Current LiabilitesSNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.57% over the past year.
SNGX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue for SNGX have been decreasing by -51.88% on average. This is quite bad
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 21.16% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.88% on average over the next years.
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SNGX Yearly Revenue VS EstimatesSNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2M 4M 6M 8M 10M
SNGX Yearly EPS VS EstimatesSNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNGX Price Earnings VS Forward Price EarningsSNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNGX Per share dataSNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as SNGX's earnings are expected to grow with 21.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.34%
EPS Next 3Y21.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLIGENIX INC

NASDAQ:SNGX (10/3/2025, 8:04:27 PM)

After market: 1.38 0 (0%)

1.38

+0.1 (+7.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners4.48%
Inst Owner Change19%
Ins Owners0.01%
Ins Owner Change0%
Market Cap11.55M
Analysts82.86
Price Target22.95 (1563.04%)
Short Float %3.58%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.24%
Min EPS beat(2)-55.11%
Max EPS beat(2)12.62%
EPS beat(4)2
Avg EPS beat(4)-7.57%
Min EPS beat(4)-55.11%
Max EPS beat(4)29.84%
EPS beat(8)5
Avg EPS beat(8)4.34%
EPS beat(12)8
Avg EPS beat(12)-10.32%
EPS beat(16)10
Avg EPS beat(16)-9.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)32.32%
EPS NY rev (1m)0%
EPS NY rev (3m)18.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB 3.24
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -184.8%
ROE -582.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z -63.72
F-Score2
WACC10.41%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
EBIT growth 1Y-49.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.28%
OCF growth 3YN/A
OCF growth 5YN/A